Education
About Us
Working with TipRanks
Follow Us
Electrocore Llc (ECOR)
NASDAQ:ECOR
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.33Last Year’s EPS
-0.38Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: -27.31%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with significant revenue growth and strategic acquisitions, but also highlighted challenges like increased operating expenses and a decline in the US prescription channel revenue. The positive aspects of revenue growth and new opportunities were tempered by operational and financial challenges.Company Guidance
During the electroCore First Quarter 2025 Earnings Conference Call, CEO Dan Goldberger provided guidance indicating a promising outlook for the company's growth trajectory. The company reported a 23% year-over-year revenue increase to $6.7 million, driven by a strong performance in the VA channel and the successful expansion of the Truvaga brand, which saw a 187% increase in net sales. Gross margins remained robust at 85%, and the company anticipates maintaining these levels. Goldberger highlighted the strategic acquisition of the Quell product line and the distribution agreement with Spark Biomedical, both of which are expected to diversify revenue streams and enhance market presence. The company is investing in sales and marketing efforts to support these initiatives, with a focus on scaling the Truvaga brand and integrating new products into existing channels. Additionally, the company is targeting a path to profitability with a goal of achieving $9 million in quarterly revenue, a 34% increase from the current quarter. The overall guidance reflects a confident outlook, emphasizing growth in core business lines and the integration of new products to capitalize on emerging opportunities in the bioelectronic technology sector.Revenue Growth
electroCore reported revenue of $6.7 million in Q1 2025, a 23% increase over Q1 2024.
Gross Margin Increase
Gross margins improved to 85% in Q1 2025, compared to 84% in Q1 2024.
Truvaga Brand Expansion
Truvaga net sales were approximately $1.1 million in Q1 2025, a 187% increase from Q1 2024.
Acquisition of NeuroMetrix's Quell Platform
The acquisition aims to accelerate electroCore's mission in the bioelectronic health and wellness sector.
New Distribution Agreement with Spark Biomedical
Agreement to distribute the Sparrow Ascent product line for the treatment of opioid withdrawal symptoms.
---
ECOR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ECOR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $6.81 | $5.19 | -23.79% |
Mar 12, 2025 | $13.00 | $9.55 | -26.54% |
Nov 13, 2024 | $13.40 | $13.60 | +1.49% |
Aug 07, 2024 | $6.10 | $6.02 | -1.31% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Electrocore Llc (ECOR) report earnings?
Electrocore Llc (ECOR) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Electrocore Llc (ECOR) earnings time?
Electrocore Llc (ECOR) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ECOR EPS forecast?
ECOR EPS forecast for the fiscal quarter 2025 (Q2) is -0.33.
---